Core Viewpoint - 10x Genomics (TXG) shares have increased by 14.7% recently, with a mean price target of $14.79 suggesting a potential upside of 55.9% from the current price of $9.49 [1][2] Price Targets and Analyst Estimates - The mean estimate consists of 14 short-term price targets with a standard deviation of $3.79, indicating variability among analysts [2] - The lowest estimate of $11 indicates a 15.9% increase, while the highest estimate suggests a 174% surge to $26 [2] - Analysts' price targets can often mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] Earnings Estimates and Analyst Agreement - Analysts are optimistic about TXG's earnings prospects, with a strong consensus on higher EPS estimates, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 14.6%, with five estimates moving higher and no negative revisions [12] - TXG holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]

Shares of Spyre Therapeutics (SYRE) have gained 14.7% over the past four weeks to close the last trading session at $14.93, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $53.50 indicates a potential upside of 258.3%.The mean estimate comprises 10 short-term price targets with a standard deviation of $16.36. While the lowest estimate of $21 indicates a 40.7% increase from the c ...

Group 1 - Dream Finders Homes Inc. (DFH) has surpassed resistance at the 50-day moving average, indicating a potential short-term bullish trend [1] - DFH has moved 8.6% higher over the last four weeks, suggesting it may be on the verge of another rally [2] - The company is currently rated as a Zacks Rank 2 (Buy), reflecting positive investor sentiment [2] Group 2 - There have been two positive earnings estimate revisions for DFH, with none being lowered for the current fiscal year, indicating strong earnings momentum [2] - The consensus earnings estimate for DFH has also increased, further strengthening the bullish outlook [2][3] - The combination of positive earnings revisions and key technical levels suggests that DFH could see more gains in the near future [3]

Core Viewpoint - Sezzle Inc. (SEZL) shows a significant improvement in earnings outlook, making it an attractive investment option as analysts continue to raise earnings estimates for the company [1][3]. Earnings Estimate Revisions - The upward trend in earnings estimate revisions indicates growing analyst optimism regarding Sezzle's earnings prospects, which is expected to positively impact its stock price [2]. - For the current quarter, Sezzle is projected to earn $0.56 per share, reflecting a 55.56% increase from the previous year [7]. - Over the last 30 days, the Zacks Consensus Estimate for Sezzle has risen by 39.13%, with two estimates moving higher and no negative revisions [7]. - For the full year, the earnings estimate is $3.24 per share, representing a 76.09% increase from the prior year [8]. - The consensus estimate for the current year has also seen positive revisions, with two estimates increasing and no negative changes [8]. Zacks Rank and Performance - Sezzle currently holds a Zacks Rank 1 (Strong Buy), indicating strong agreement among analysts in raising earnings estimates [9]. - The Zacks Rank system has a proven track record, with Zacks 1 Ranked stocks averaging a 25% annual return since 2008 [3]. - Stocks with Zacks Rank 1 and 2 significantly outperform the S&P 500, suggesting a favorable investment environment for Sezzle [9]. Stock Performance - Sezzle shares have increased by 125.6% over the past four weeks, indicating strong investor confidence in the company's earnings growth prospects [10].

Core Viewpoint - OppFi Inc. (OPFI) is showing a significantly improving earnings outlook, making it an attractive option for investors as analysts continue to raise their earnings estimates for the company [1][2]. Earnings Estimate Revisions - Analysts' optimism regarding OppFi's earnings prospects is leading to higher estimates, which is expected to positively impact the stock price [2]. - The Zacks Rank system indicates a strong correlation between earnings estimate revisions and stock price movements, with Zacks 1 Ranked stocks averaging a +25% annual return since 2008 [3]. - The consensus estimate for the current quarter has increased by 7.27% over the last 30 days, with the current-quarter estimate at $0.30 per share, reflecting a +3.45% change year-over-year [7]. - For the full year, OppFi is projected to earn $1.16 per share, representing a +22.11% year-over-year change, with a 15.89% increase in consensus estimates over the past month [8][9]. Zacks Rank and Investment Potential - OppFi currently holds a Zacks Rank 1 (Strong Buy) due to favorable estimate revisions, indicating strong potential for outperformance compared to the S&P 500 [10]. - The stock has appreciated by 37.4% over the past four weeks, suggesting that further upside may still be possible, making it a candidate for portfolio addition [11].

Investors might want to bet on GSK (GSK) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individual investors ...

Clover Health Investments, Corp. (CLOV) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and follo ...

Core Viewpoint - DexCom (DXCM) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][2]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [3][5]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [3]. Company Performance and Outlook - The upgrade for DexCom reflects an improvement in its underlying business, suggesting that investor sentiment may drive the stock price higher [4]. - DexCom is projected to earn $2.02 per share for the fiscal year ending December 2025, representing a year-over-year increase of 23.2% [7]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [6]. - DexCom's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [9].

Group 1 - AppLovin (APP) shares have increased by 31.4% over the past four weeks, closing at $328.54, with a mean price target of $448.30 indicating a potential upside of 36.5% [1] - The average of 20 short-term price targets ranges from a low of $200 to a high of $650, with a standard deviation of $122.50, suggesting variability in analyst estimates [2] - Analysts have shown a strong agreement in revising earnings estimates higher, with four estimates moving up in the last 30 days and no negative revisions, leading to a 14.2% increase in the Zacks Consensus Estimate [11][12] Group 2 - The Zacks Rank for APP is 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13] - While price targets are often viewed as a key metric, they can mislead investors, and analysts may set overly optimistic targets due to business incentives [7][8][10] - A low standard deviation in price targets indicates a high degree of agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9]

Avadel (AVDL) closed the last trading session at $9.39, gaining 22.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $18.80 indicates a 100.2% upside potential.The average comprises 10 short-term price targets ranging from a low of $12 to a high of $27, with a standard deviation of $4.59. While the lowest estimate indicates an increase of 27.8% from the current price level, the mo ...